Scholars Central

Review articlePublished 22 Jul 2016

An update on drug-eluting stents versus bare-metal stents in PCI treatment: are there any remaining indications for BMS use?

Authors: GG Stefanini, B Meier

Interventional Cardiology

Volume 7 · Issue 5 · Pages 497–506

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Drug-eluting stents (DES) are recognized as a breakthrough technology in the treatment of coronary artery disease, primarily due to substantial reduction in the risk of repeat revascularization as compared with bare-metal stents (BMS). During the last decade new DES – with thinner stent struts, novel durable or biodegradable polymer coatings, and new limus antiproliferative agents – have been developed to address the limitations of earlier generation DES. Randomized trials, observational studies and meta-analyses have shown a marked improvement in clinical safety and efficacy with new-generation DES as compared with BMS, as well as early-generation DES, in a wide spectrum of patients. The objective of this article is to review whether there are any indications left for the use of BMS in clinical practice based on available evidence.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInterventional Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “GG Stefanini”
  • BylineArticles whose byline prints “B Meier”